US FDA finally ready to start supply chain pilot
This article was originally published in SRA
Executive Summary
More than four years ago, the US Food and Drug Administration said it was launching a new program aimed allowing the agency to focus its resources on drugs brought into the US that pose the greatest risks to consumers, while expediting the entry of specific finished medicines and active pharmaceutical ingredients (APIs) that meet certain criteria.